Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[177Lu]Lu-DOTA-PN983 is a novel radiolabeled small molecule antagonist targeting the neurokinin-1 receptor (NK1R), developed by researchers at Uppsala University and the Science for Life Laboratory (SciLifeLab) in Sweden. The compound consists of the NK1R-targeting phenylpiperidine-based ligand PN983 conjugated to the chelator DOTA and radiolabeled with the beta-emitting radionuclide lutetium-177 (177Lu). NK1R is a G-protein coupled receptor that is overexpressed in several malignancies, including glioblastoma, neuroblastoma, and breast cancer. In preclinical studies, [177Lu]Lu-DOTA-PN983 demonstrated high binding affinity to NK1R (KD = 4 nM) and favorable in vivo biodistribution, showing rapid tumor uptake and high tumor-to-blood ratios, making it a promising candidate for targeted radionuclide therapy and SPECT/CT imaging of NK1R-positive tumors.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | Preclinical | Active |
| glioblastoma, IDH-wildtype | Preclinical | Active |
| neuroblastoma | Preclinical | Active |
| neuroblastoma (MYCN-amplified / non-amplified) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [177Lu]Lu-DOTA-PN983.
Work on [177Lu]Lu-DOTA-PN983? Claim this page to correct or add information. Claim this page